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Available online 11 January 2016Background: Genome-wide association studies have identiﬁed polymorphisms linked to both smoking exposure
and risk of lung cancer. The degree to which lung cancer risk is driven by increased smoking, genetics, or gene–
environment interactions is not well understood.
Methods:We analyzed associations between 28 single nucleotide polymorphisms (SNPs) previously associated
with smoking quantity and lung cancer in 7156 African-American females in the Women's Health Initiative
(WHI), then analyzed main effects of top nominally signiﬁcant SNPs and interactions between SNPs, cigarettes
per day (CPD) and pack-years for lung cancer in an independent, multi-center case–control study of African-
American females and males (1078 lung cancer cases and 822 controls).
Findings:Nine nominally signiﬁcant SNPs for CPD inWHIwere associatedwith incident lung cancer (corrected p-
values from 0.027 to 6.09 × 10−5). CPDwas found to be a nominally signiﬁcant effectmodiﬁer between SNP and
lung cancer for six SNPs, including CHRNA5 rs2036527[A](betaSNP*CPD =−0.017, p = 0.0061, corrected p =
0.054), which was associated with CPD in a previous genome-wide meta-analysis of African-Americans.
Interpretation: These results suggest that chromosome 15q25.1 variants are robustly associated with CPD and
lung cancer in African-Americans and that the allelic dose effect of these polymorphisms on lung cancer risk is
most pronounced in lighter smokers.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Smoking. This is an open access article under1. Introduction
It is well established that tobacco smoking is responsible for most of
the attributable risk of lung cancer, which is the leading cause of cancerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Human-Services, 2014). However, there is also growing evidence that
genetic factors contribute to risk for developing lung cancer (Fisher,
1958a; Fisher, 1958b; Sullivan and Kendler, 1999; Li et al., 2003; Maes
et al., 1999; Heath, 1990; Raaschou-Nielsen, 1960; Crumpacker et al.,
1979; Eaves et al., 1993; Carmelli et al., 1992; Kaprio et al., 1984;
Edwards et al., 1995; Hannah et al., 1985; Heath et al., 1993; Vink
et al., 2005; Lessov et al., 2004; Broms et al., 2006). Genome-wide
meta-analyses (GWAS) of linkage studies of smoking behaviors in
European ancestry populations have identiﬁed three genomic regions
with genome-wide suggestive or signiﬁcant evidence for ever-
smoking on chromosomes 5 (q33.1–5q35.2) and 17 (q24.3–q25.3)
and maximum cigarettes smoked per day on chromosome 20
(q13.12–q13.32) (Han et al., 2010). Candidate gene association studies
of smoking have had limited success in identifying replicable associa-
tions (Hirschhorn et al., 2002; Lohmueller et al., 2003; Munafo et al.,
2004). Variation in the CYP2A6 locus, which plays the primary role in
nicotine metabolism, has emerged as reliably inﬂuencing smoking be-
havior (Tyndale and Sellers, 2002) but slow metabolizing variants are
uncommon in African-descent populations (Piliguian et al., 2014).
In GWAS, several single-nucleotide polymorphisms (SNPs) have
been identiﬁed as being associated with lung cancer or smoking behav-
ior. The rs1051730 SNPwithin the nicotinic acetylcholine receptor gene
cluster (CHRNA5/CHRNA3/CHRNB4) cluster on chromosome 15q25.1
has been identiﬁed with being associated with both quantity of ciga-
rettes smoked per day and lung cancer risk (Thorgeirsson et al., 2008).
The relationship between CHRNA5-A3-B4 loci and smoking quantity
has been replicated in European-ancestry smokers in large GWAS
datasets including the European Network of Genomic and Genetic Epi-
demiology (ENGAGE) Consortium (Thorgeirsson et al., 2010). More-
over, a large (N140,000 European-ancestry samples) GWAS by the
Tobacco and Genetics Consortium conﬁrmed an association between
two SNPs in the CHRNA5/CHRNA3/CHRNB4 gene cluster with cigarettes
per day (CPD) for rs1051730 (p = 2.8 × 10−73) and rs1696998 (p =
5.6 × 10−72) (Tobacco-and-Genetics-(TAG)-Consortium, 2010). Anoth-
ermeta-analysis (Saccone et al., 2010) reported that rs16969968,which
is highly correlatedwith rs1051730, and rs588765 (separate loci within
the chromosome 15q25.1 region) were both statistically-signiﬁcantly
associated with smoking quantity and lung cancer risk and chronic ob-
structive pulmonary disease (COPD) and emphysema after adjustment
for average reported CPD. Given that smoking is causally related to
both COPD/emphysema and lung cancer and that COPD/emphysema
is considered a precursor condition to carcinoma of the lung (Etzel
et al., 2008) and mediator of the relationship between smoking and
lung cancer (Young et al., 2009), the mechanistic nature of the rela-
tionship between the chromosome 15q25.1 locus and risk of lung
cancer, i.e., the degree to which smoking quantity is an effect-
modiﬁer, mediator or confound, remains a subject of ongoing inves-
tigation. In addition to chromosome 15q25.1, nine other regions
have been associated with lung cancer susceptibility in European
and Asian ancestry populations (Wang et al., 2015), though not all
these regions have been replicated.
Exploration of genetic biomarkers for lung cancer risk is needed in
non-European populations such as African-ancestry populations be-
cause of population differences in disease allele frequency, linkage dis-
equilibrium patterns and phenotype prevalence (Rosenberg et al.,
2010). African Americans, on average, initiate smoking later, smoke
fewer CPD, yet are less likely to successfully quit smoking and have a
higher risk of smoking-related lung cancer thanmany other populations
(Haiman et al., 2006). Ethnic differences in clearance of metabolites
have been shown to contribute to the observed differences in cigarette
consumption across populations, mediated in part by variants in the cy-
tochrome p450 2A6 (CYP2A6) gene, but these alleles are less common in
individuals of African-descent which makes this locus less likely to be
responsible for increased lung cancer risk (Benowitz et al., 2011;
Mwenifumbo et al., 2007; Moolchan et al., 2003).We seek to examine the hypothesis that the association between
SNPs in this region and lung cancer is moderated by smoking quantity,
through conducting a candidate gene based analysis in African-
American WHI SNP Health Association Resource (SHARe) participants
to identify nominal SNPs linked to lung cancer that are associated
with smoking quantity, and then to conduct gene × smoking quantity
interaction analyses in participants from a multicenter case–control
study of lung cancer.
2. Material and Methods
2.1. Study Population
The WHI SHARe study population consisted of 7156 females, of
which 7097 were healthy and 59 had been diagnosed with lung cancer
for whom genotype, smoking variables and lung cancer status were
available. Additional details about the methods of the larger WHI
Study (Stefanick et al., 2003; Langer et al., 2003) and the WHI SHARe
cohort (Langer et al., 2003; David et al., 2012) have been previously re-
ported. The study population analyzed for lung cancer susceptibility
were from a previously-described multicenter case–control study de-
signed to include African-American lung cancer cases and controls
from three collaborating institutions: University of California, San
Francisco (UCSF) (447 cases & 453 controls); Wayne State University
(WSU) (459 cases & 460 controls) and the MD Anderson Cancer Center
(MDA) (479 cases & 376 controls) (Walsh et al., 2013). Theﬁnal analytic
sample from the multicenter case–control study included 1078 cases
and 822 controls. Never smokers were excluded from interaction
analyses.
The genotype data were generated from DNA extracted from
whole blood samples and imputed using 1000 Genomes (Genomes
Project et al., 2012), downloaded from dbGaP (dbGaP accession
#phs000200.v10.p3.c1; protocol #4723). The data available on
dbGaP contained imputed genotype information along with vari-
ables of interest such as age, CPD, and other covariates. This investi-
gation was approved by the Stanford University Institutional Review
Board (IRB) (Stanford IRB #27009) and the IRBs of the Women's
Health Initiative and all participating institutions of the multi-
center case–control study.
2.2. SNP Selection
Based upon the evidence from GWAS and ﬁne-mapping studies of
African-Americans, we selected 28 SNPs in the chromosome 15p12.33
and 15q25.1 regions reported in one or more studies of African-
Americans to be associated with risk of lung cancer and/or smoking
quantity (CHRNA3 rs1051730 (Amos et al., 2010), rs10519203 (Amos
et al., 2010; Spitz et al., 2013), rs578776 (Hansen et al., 2010),
rs4243084 (Walsh et al., 2012), and rs8029939 (Hansen et al., 2010);
CHRNA5 rs11637635 (Hansen et al., 2010), rs169969968 (Walsh et al.,
2012; Chen et al., 2012), rs17408276 (Hansen et al., 2010),
rs17486278 (Walsh et al., 2013; Hansen et al., 2010), rs17486195
(Walsh et al., 2013), rs2036527 (David et al., 2012; Walsh et al., 2013;
Walsh et al., 2012), rs564585 (Hansen et al., 2010), rs667282 (David
et al., 2012; Amos et al., 2010), rs684513 (Amos et al., 2010), 7180002
(Walsh et al., 2013), and rs951255 (Hansen et al., 2010; Walsh et al.,
2013); IREB2 rs17405217 (Walsh et al., 2013; Walsh et al., 2012);
LOC123688 rs11852372 (Hansen et al., 2010), rs7164594 (Amos et al.,
2010; Hansen et al., 2010), and rs7168796 (Hansen et al., 2010); RORA
rs8031948 (Amos et al., 2010); and on 5p15.33, TERT rs2735940
(Walsh et al., 2013) and rs4635969 (Walsh et al., 2013).We also includ-
ed SNPs associated with smoking quantity that achieved (CHRNA5
rs2036527) or approached genome-wide signiﬁcance from the STOMP
meta-GWAS (CHRNA5 rs667282, CHRNA3 rs938682, C1orf100
rs3101457, LOC503519 rs547843 and PSMA4 rs3813570) (David et al.,
2012).
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2.3.1. Smoking Exposure Variables, Genotyping and Quality Control (QC) in
WHI SHARe
All WHI SHARe samples were genotyped at the Fred Hutchinson
Cancer Research Center using Affymetrix 6.0 arrays. SNPs with call-
rates b95%, b1% minor allele frequency or signiﬁcant (P b 10−6)
departure from Hardy–Weinberg equilibrium were excluded, as were
individuals with excess autosomal heterozygosity, mismatch between
reported and genetically determined sex, or ﬁrst- or second-degree
relatedness. Smokers were individuals reporting having smoked at
least 100 cigarettes in their lifetime. Current smokers were individuals
who reported smoking at their baseline assessment. Cigarettes per
day, a categorical variable in WHI's dataset (b1, 1–4, 5–14, 15–24, 25–
34, 35–44, N45), were converted to a quasi-continuous variable by
using themidpoint of each level of the original variable as its continuous
value, e.g., the 1–4 cigarette per day category would have a continuous
value of 2.5. Women in the b1 category were assigned 0 cigarettes per
day and women who reported smoking N45 were assigned 50. Pack-
years were calculated as the number of cigarettes per day multiplied
by the duration of a subject's smoking habit divided by 20 (David
et al., 2012).
2.3.2. Analysis of WHI SHARe Samples
WHI genotype data were downloaded from dbGaP ﬁles. Prior to
dbGaP deposition, principal components analysis and frappe analy-
sis were performed for all genotyped SNPs ﬁrst on all WHI samples
and then towards African-American samples separately. Principal
components analysis (PCA) was applied to African, European, Native
American and East Asian separately for ﬁve iterations to remove self-
identiﬁed African-American individuals with less than 20% African,
resulting in an average of 80% African ancestry (David et al., 2012).
Eigenstrat computes the eigenvectors (principle components) of a
set of independent SNPs. These principal components were used as
covariates in all phenotype association analyses (Price et al., 2006).
Frappe is a model-based clustering program that estimates ancestry
proportions, determining what percentage of the genome for any
African-American individual is African and what percentage is
European (Tang et al., 2005). Genome-wide Complex Trait Analysis
(GCTA) was applied to the genotyped SNPs having a quality score
greater than 0.98 in the 1000 Genome imputed data (Yang et al.,
2011). SNPs with quality scores ≤0.98 were excluded (David et al.,Fig. 1. Sample size ﬂow chart. Legend: Description of analytic sample with available genetic, s
Polymorphism Health Association Resource (SHARe) and (B) Multicenter Lung Cancer Case–
(dbGaP accession #4723: Gene by environment interactions for lung cancer in cohort of Afric
salient variables. The ﬁnal WHI SHARe cohort included 7156 women with 59 cases of lung can
controls in the multicenter case–control study of lung cancer. We excluded 50 lung cancer case
trols as the ﬁnal study population. When modeling interactions, never-smokers were excluded2012). Fig. 1 provides details on the sample size adjustments for sub-
jects removed for reasons of admixture, or missing phenotype data.
From WHI SHARe, 1265 subjects out of 8421 genotyped subjects
(15%) were excluded for missing smoking or outcomes data or be-
cause of non-African ancestry (deﬁned above), of which 213 (2.5%)
for non-African ancestry outliers.
PCA was performed on theWHI genotype data and the top principal
components were subsequently used as covariates to adjust for admix-
ture. For each SNP we ﬁt linear regression models with CPD as the de-
pendent variable and SNP genotypes as the independent variable
while adjusting for age and the ﬁrst ﬁve principal components. All
SNPs were coded using an additive risk scheme with the minor allele
as the risk allele. Our results were consistent in a sensitivity analysis
using only the ﬁrst principal component and using the ﬁrst 20 principal
components.
As a secondary analysis, we reﬁt the cigarette exposuremodels using
pack-years as the dependent variable.We addressedmultiple testing is-
sues by adjusting the family-wise error rate using the Bonferroni meth-
od. The p-values from the models for the ﬁt to WHI data were
Bonferroni adjusted separately from the p-values resulting from the
case–control data.
A haplotype map was generated including the top SNPs in order to
determine D′ and r2 between the chromosome 15q25.1 SNPs associated
with CPD to assess degree of linkage disequilibriumbetweenpotentially
correlated loci in the same genomic region (Fig. 2).2.3.3. Smoking Exposure, Lung Cancer Variables, Genotyping and QC in
Multicenter Case–Control Study
UCSF samples were genotyped at the UCSF Genome Center, WSU
samples were genotyped at the WSU Applied Genomics Technology
Center, and MDA samples were genotyped at the MDA Cancer Center
— all centers using the same Illumina Golden Gate Custom panel of
1536 SNPs (Walsh et al., 2013). Genotype reproducibility was veriﬁed
with 7 duplicate samples, with concordance ranging from 99.93% to
100%. For all study sites, samples with genotyping call-rates less than
95% were excluded from analyses. SNPs with call-rates less than 95%
in more than one study sites were excluded for analyses. To exclude
poorly genotyped SNPs, any SNP with Hardy–Weinberg Equilibrium P
value b1.0 × 10−4 in controls, stratiﬁed by site, was removed from anal-
ysis. All SNP quality control was carried out using Plink v1.07 (Purcell
et al., 2007).moking and lung cancer data for (A) Women's Health Initiative (WHI) Single Nucleotide
Control Study. There were 8421 women in the downloaded dbGaP data for WHI SHARe
an-American women in Women's Health Initiative), and 1265 were excluded for missing
cer and 29 cases of lung cancer mortality. There were 1,358 lung cancer cases and 1,289
s and 419 controls because of missing data, leaving 1,308 lung cancer cases and 1,241 con-
, leaving 1078 cases and 822 controls.
Fig. 2. Patterns of linkage disequilibrium in the chromosome 15q24–25.1 region. Legend: Panel a represents D’ and panel b represents r2 values. Darker shading indicates higher r2 values
and greater correlation between the SNPs.
156 S.P. David et al. / EBioMedicine 4 (2016) 153–161Cancer histologywas determined using ICD-O codes abstracted from
Surveillance Epidemiology and End Results (SEER) data from the Cali-
fornia Cancer Registry (UCSF cases) or Detroit Cancer Registry (WSU
cases). ForMD-Anderson cases, histologywas determined by extraction
from medical records. The following ICD-O groupings were made: ade-
nocarcinoma (ICD-O: 8140, 8230, 8250–8255, 8260, 8310, 8333, 8470,
8480, 8481, 8490, and 8550), squamous cell carcinoma (8052,
8070–8073, 8083, and 8084), and small cell carcinoma (8041–8045)(Walsh et al., 2013). Each of these diagnostic subtypes of lung cancer
were pooled as a singular ‘lung cancer’ diagnosis for the purposes of
the present investigation.
2.3.4. Analysis of Multicenter Case–Control Study Samples
Structure v2.3.1 was used to estimate percentage of membership in
3 distinct founder populations: sub-Saharan African, European, and East
Asian, with East Asian ancestry as a proxy for American Indian descent
157S.P. David et al. / EBioMedicine 4 (2016) 153–161(International HapMap C, 2003). Founder population allele frequencies
were deﬁned using SNP data from 102 unlinked (r2 b 0.20) ancestry in-
formative markers, genotyped in 502 unrelated HapMap individuals
(167 Yoruban Africans, 165 Europeans, 84 Chinese, and 86 Japanese).
These same AIMs were genotyped in study participants for use with
the Structure program (Walsh et al., 2013; Pritchard et al., 2000). PCA
was performed on the multicenter case control genotype data and the
top principal components were subsequently used as covariates to
adjust for admixture. For the 9 available SNPs with the smallest p-
values on the association between CPD and SNP, we ﬁt logistic regres-
sion models where probability of lung cancer incidence was modeled
with a logit link. These models were all adjusted for age, sex, study
site, and percent African ancestry using ﬁrst ﬁve principal components.
As a secondary analysis, we reﬁt the cigarette exposure model
using pack-years in place of CPD. All models were reﬁt with an interac-
tion term between SNP and CPD or SNP and pack-years using the case–
control data.
All SNP quality control was carried out using Plink v1.07 (Purcell
et al., 2007). Haploview was used to generate haplotype maps (Fig. 1)
(Barrett et al., 2005). WHI SHARe analyses were conducted in R 3.1 (R
Foundation for Statistical Computing, Vienna, Austria) (R Foundation
for Statistical Computing, 2013). The analyses on the samples from the
multicenter case–control study were conducted in SAS v9. P-values
b0.05 were considered to be statistically signiﬁcant.3. Results
The WHI SHARe genetic cohort included N = 8421 female individ-
uals. After excluding women without genotype data and women who
were missing relevant variables, 7156 women remained (Fig. 1), of
which 2765 (39%) were former smokers, 779 (11%) were current
smokers and 3612 (50%) were never smokers. The mean age of partici-
pants was 61 years (standard deviation (SD) = 6.8) for healthy and
63.6 years (SD = 6.6) for lung cancer cases. The multicenter case–con-
trol study analytic cohort included N = 1900 female and male individ-
uals, of which 934 (49%) were female, of which 751 (39%) were ever
smokers, 778 (40.9%)were current smokers and 295 (15%)were former
smokers. Themean age of participantswas 62 years (standard deviation
(SD) = 10) for healthy and 62 years (SD = 10) for lung cancer cases.
Additional details including smoking history and demographics are de-
scribed in Table 1 with extended descriptions published elsewhere
(David et al., 2012; Walsh et al., 2013).
The results of analyses of all included SNPs on CPD in theWHI SHARe
sample are presented in Table 2. In the models with CPD as their out-
come in the WHI SHARe cohort, 1 SNP was found to be associated
with CPD following Bonferroni adjustment), rs1051730 (adjusted p=
0.027). For this SNP, each additional A allele increased subjects'Table 1
Participant characteristics.
Total
(%)
Female
(%)
Male
(%)
Never smokers
(%)
Current s
(%)
WHI SHARe
Healthy
N = 7097 (99.2%) 7097 (100.0%) – 3,598 (50.7%) 761 (10.
Lung cancer
N = 59 (0.8%) 59 (0.08%) – 14 (23.7%) 18 (30.
UCSF, MD Anderson & Wayne State University Case–Control
Healthy
N = 822 (43.3%) 404 (49.1%) 418 (50.9%) NA 435 (52.
Lung cancer
N = 1078 (56.7%) 530 (49.2%) 548 (50.8%) NA 660 (61.
Legend: Abbreviations:WHI=Women's Health Initiative; SHARe=Single Nucleotide Polymor
cancer.
Note. The WHI study included only females. Never-smokers were not included in analyses of luexpected number of CPD by 0.081 cigarettes. In addition, 10 other
SNPs were nominally signiﬁcant for associationwith CPD but not statis-
tically signiﬁcant following Bonferroni correction.
Given the low number of lung cancer cases in theWHI sample (n=
86), we sought to conduct interaction analyses for the top 10 nominal
SNPs for CPD from the WHI SHARe population in the multicenter lung
cancer case–control study population described above. Genotype data
were available for nine of these SNPs, with no data available for
rs547843. The results for analyses of main effects of nominally signiﬁ-
cantWHI SHARe CPD SNPs on lung cancer in themulticenter case–con-
trol study are presented in Table 3. All nine SNPs were statistically
signiﬁcantly associated with lung cancer (Bonferroni-corrected P-
values from 0.027 to 6.09 × 10−5). There were six SNPs that demon-
strated nominally signiﬁcant interactions with CPD for risk of incident
lung cancer (Table 4), two of which approached statistical signiﬁcance
after Bonferroni correction: rs2036527[A], beta = −0.0171, p =
0.0549; rs7180002, beta =−0.0205, p= 0.0576.
Fig. 3 illustrates the allele dose response relationships for each of
these SNPs with incident lung cancer as estimated in the interaction
models. The nature of each of these interactions was notable for a pat-
tern suggesting – but not establishing, given that the interactions
were not statistically signiﬁcant after Bonferroni correction – stronger
allele dose-responses for individuals who smoked fewer CPD. Odds ra-
tios for lung cancer risk by average CPD are presented in Supplementary
Materials.4. Discussion
To our knowledge, there have been at least four ﬁne-mapping case
control studies of lung cancer in African Americans that have examined
the chromosome 15q25.1 locus and additional loci on chromosomes
5p15.33 and 6p22.1–21.31 (Walsh et al., 2013; Amos et al., 2010; Spitz
et al., 2013; Hansen et al., 2010). One study of 1058 cases and 1314 con-
trols from the Detroit area Surveillance, Epidemiology, and End Results
(SEER) registry found that SNP rs1051730 on chromosome15q25.1was
associated with lung cancer in African-American ever-smokers
(Schwartz et al., 2009) — ﬁndings similar to a larger study of
European-ancestry cases (n = 1024) and controls (n = 32,244)
(Thorgeirsson et al., 2008). Another study identiﬁed multiple SNPs
and a haplotypewithin the chromosome 15q25.1 region with lung can-
cer in 448 African-American lung cancer cases and 611 controls, which
suggests that SNPs in this region affecting expression of the alpha 5
(CHRNA5), alpha 3 (CHRNA3) and beta 4 (CHRNB4) nicotinic acetylcho-
line receptor genes may be independently associated with lung cancer
(Amos et al., 2010; Hansen et al., 2010).
In a previously published meta-analysis using data from the WHI
SHARe cohort (n= 8208) and twelve other study groups forming themokers Former smokers
(%)
Age, mean
(SD)
Age of onset, mean
(SD)
CPD, mean
(SD)
7%) 2,738 (38.6%) 61.0 (6.8) 20.9 (5.4) 5.5 (8.5)
5%) 27 (45.8%) 63.6 (6.6) 19.5 (4.1) 14.4 (12.4)
9%) 387 (47.1%) 60.5 (10.2) 16.9 (4.6) 17.9 (13.9)
2%) 418 (38.8%) 63.0 (10.3) 17.6 (4.9) 20.2 (13.1)
phismHealth Association Resource; SD= standard deviation; %=percent healthy or lung
ng cancer outcomes.
Table 2
SNPs analyzed for association with cigarettes per day in WHI SHARe.
SNP Chromosome (base-pair) position Nearby genes Alleles Coded Allele Coded AF ß (s.e.) P-value P-value (adjusted)*
rs1051730 15:78601997 CHRNA3 G/A A 0.13145 0.081 (0.029) 0.00095 0.02669
rs7180002 15:78581651 CHRNA5 A/T T 0.11941 0.072 (0.034) 0.00307 0.08597
rs951266 15:78586199 CHRNA5 G/A A 0.11944 0.069 (0.035) 0.00383 0.10718
rs2036527 15:78559273 CHRNA5 G/A A 0.22451 0.077 (0.029) 0.00388 0.10872
rs17486278 15:78575140 CHRNA5 A/C C 0.28691 0.072 (0.026) 0.00492 0.13772
rs16969968 15:78590583 CHRNA5 G/A A 0.08021 0.059 (0.036) 0.00725 0.20295
rs4243084 15:78619330 CHRNA3 G/C C 0.20197 0.072 (0.028) 0.00745 0.20854
rs17405217 15:78438807 IREB2 C/T T 0.09058 0.056 (0.033) 0.01213 0.33967
rs547843 15:26178900 LOC503519 C/G G 0.35954 0.068 (0.029) 0.01740 0.48725
rs938682 15:78604205 CHRNA3 A/G G 0.28587 −0.049 (0.025) 0.02642 0.73971
rs11852372 15:78509052 HYKK A/C C 0.16997 0.040 (0.029) 0.03982 1
rs478776 15:78596058 CHRNA3 A/G G 0.47358 0.029 (0.024) 0.05376 1
rs8031948 15:78523715 HYKK G/T T 0.18103 0.043 (0.028) 0.05791 1
rs10519203 15:78521704 HYKK A/G G 0.32025 0.042 (0.025) 0.11335 1
rs564585 15:78593885 CHRNA3 G/A A 0.47403 0.016 (0.026) 0.12637 1
rs17408276 15:78589276 CHRNA5 T/C C 0.1458 −0.062 (0.029) 0.19065 1
rs7164594 15:78510715 HYKK C/T T 0.40943 −0.020 (0.024) 0.19103 1
rs11637635 15:78584808 CHRNA5 G/A A 0.28379 −0.044 (0.026) 0.19106 1
rs3101457 1:244369912 C1orf100 A/G G 0.2478 0.072 (0.049) 0.23023 1
rs3813570 15:78540490 PSMA4 T/C C 0.27113 −0.027 (0.027) 0.28473 1
rs2735940 5:1296371 TERT G/A A 0.49586 −0.028 (0.033) 0.32441 1
rs17486195 15:78572855 CHRNA5 A/G G 0.13368 0.012 (0.029) 0.33791 1
rs8029939 15:78596007 CHRNA3 G/A A 0.12207 0.053 (0.035) 0.34905 1
rs4635969 5:1308437 TERT G/A A 0.31211 0.031 (0.025) 0.40241 1
rs667282 15:78571130 CHRNA5 T/C C 0.2945 −0.024 (0.026) 0.48116 1
rs7168796 15:78508152 HYKK T/C C 0.16283 0.048 (0.031) 0.52338 1
rs9672189 15:78509054 HYKK A/C C 0.15226 0.030 (0.028) 0.69760 1
rs684513 15:78566058 CHRNA5 C/G G 0.13145 −0.013 (0.031) 0.89055 1
Legend: Abbreviations: AF, allele frequency; SNP, single-nucleotide polymorphism. Coded AF refers to the allele analyzed as the predictor allele; it is not necessarily the minor allele. All
SNPs coded to NCBI Build 38/UCSC hg38 forward strand. *Bonferronni-adjusted P-value. Beta (ß) and standard error (s.e.) for change in CPD per increase in additive risk (increase in pres-
ence of coded allele.
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sortium (N = 32,829 (David et al., 2012), rs2036527 was associated
with CPD in African-Americans (David et al., 2012), which has subse-
quently been shown to portend increased potential beneﬁt from
smoking cessation treatment in treatment-seeking African-Americans
smokers (Zhu et al., 2014). The s2036527 SNP is located in the 5′ distal
enhancer region of the CHRNA5 gene, which forms a haplotype associat-
ed with increased CHRNA5 expression (Smith et al., 2011) and which
has been associated with lung cancer in three ﬁne-mapping studies of
African Americans (Walsh et al., 2013; Amos et al., 2010; Hansen
et al., 2010). However, mechanisms conferring increased risk for any
of the highly correlated SNPs in this region are complex andmay involve
epigenetic effects on the CHRNB4 and TERT genes (Scherf et al., 2013)
and decreased apoptosis in tumor cells resulting from over-expressionTable 3
Associations between Nominal SNPs associatedwith cigarettes per day inWHI SHARe and
lung cancer in African Americans in WHI SHARe and multicenter case–control study.
Gene SNP ß (s.e.) P Adj. P⁎
CHRNA5 rs17486278 0.295 (0.061) 1.66 × 10−06 1.49 × 10−05
CHRNA5 rs2036527 0.302 (0.067) 6.77 × 10−06 6.09 × 10−5
CHRNA3 rs1051730 0.374 (0.085) 1.18 × 10−05 1.06 × 10−04
CHRNA5 rs16969968 0.451 (0.115) 5.43 × 10−05 4.89 × 10−04
CHRNA5 rs7180002 0.344 (0.088) 9.57 × 10−05 8.61 × 10−4
CHRNA3 rs4243084 0.278 (0.071) 9.86 × 10−05 8.87 × 10−04
CHRNA5 rs951266 0.333 (0.088) 0.00015 0.001
CHRNA3 rs938682 −0.192 (0.065) 0.00301 0.027
IREB2 rs17405217 0.339 (0.115) 0.0032 0.029
Legend: SNP AFs in multicenter case–control reported elsewhere); (Walsh et al., 2013)
Beta (ß) and standard error (s.e.) for change in CPD per increase in additive risk (increase
in presence of coded allele) for WHI SHARe and for lung cancer risk in Multicenter Case–
Control Study of Lung Cancer.
⁎ Bonferroni-adjusted p-value. The p-values were adjusted by a factor of 9. Although
nominally associated with CPD inWHI SHARe, rs547843 was not genotyped in theMulti-
Center Case–Control Study.of the PSMA4 gene, which has been suggested for rs2036527 (Liu
et al., 2009).
The functional SNP rs16969968, which results in an amino acid
change conferring increased alpha 5 nicotinic acetylcholine receptor
expression (Bierut et al., 2008), was associated with CPD but was not
reach nominal signiﬁcance for effect modiﬁcation of CPD for lung
cancer. Rs1051730 was also associated with CPD. Although
rs169969968 and rs1051730 are highly correlated with each other
in European-ancestry populations (r2 = 1), they are less correlated
in African-ancestry (r2 = 0.4) (HapMap3 Release 2 ASW). Both
SNPs are rare or monomorphic in sub-Saharan Africans and
African-Americans (David et al., 2012; Chen et al., 2012), and in the
US-based WHI SHARe study population the minor alleles for both
SNPs were relatively infrequent (mean allele frequencies for
rs169969968 and rs1051730 are 0.08 and 0.13, respectively) com-
pared to rs2036527 (MAF= 0.22) (Table 2). Our previous results in-
dicated that rs2036527 was the primary index signal for CPD in
African-Americans (David et al., 2012) after conditioning on this
SNP. The STOMP meta-GWAS results suggested that the secondary
SNP signals for CPD in African-Americans were likely the result of
high linkage disequilibrium, indicating that the rs2036527 variant
may be the most informative marker of heightened smoking expo-
sure in African-Americans. Of note, neither rs16969968 nor
rs1051730 approached genome-wide signiﬁcance in the meta-
analyses of over 32,000 African-Americans. Alternatively, less robust
associations for these SNPs in African-Americans could also be inﬂu-
enced by reduced power resulting from diminished linkage
disequilbrium smaller haplotype blocks and lower minor allele
frequencies.
Asmentioned above, only 11 of 29 SNPs testedwere nominally asso-
ciatedwith CPD. Lack of statistical signiﬁcance for CPD formany of these
variants could be explained either by small effect sizes for this pheno-
type, requiring larger sample sizes to detect and the possibility that
some variants previously linked to lung cancer but not to CPD
(e.g., HYKK rs11852372) (Fehringer et al., 2012) could operate through
Table 4
Interaction analyses for incident lung cancer.
Pack-year × SNP interaction CPD × SNP interaction
rsID Effect allele ß (s.e.)SNP⁎PackYrs PSNP⁎PackYears Bonferroni P ß (s.e.)SNP⁎CPD PSNP⁎CPD Bonferroni P
rs2036527 A −0.0029 (0.004) 0.4448 1 −0.0171 (0.006) 0.0061 0.0549
rs7180002 T −0.0026 (0.005) 0.5878 1 −0.0205 (0.008) 0.0064 0.0576
rs17486278 C −0.0037 (0.003) 0.2738 1 −0.0140 (0.006) 0.0081 0.0729
rs951266 A −0.0022 (0.005) 0.6585 1 −0.0197 (0.008) 0.0089 0.0801
rs1051730 A −0.004 (0.005) 0.4418 1 −0.0183 (0.007) 0.0112 0.1008
rs17405217 T b0.001 (0.007) 0.9546 1 −0.0251 (0.010) 0.0136 0.1224
rs16969968 A 0.0057 (0.007) 0.4049 1 −0.018 (0.010) 0.0754 0.6786
rs4243084 C 0.0024 (0.004) 0.5524 1 −0.008 (0.006) 0.1959 1
rs938682 G −0.003 (0.004) 0.4581 1 −0.0035 (0.006) 0.5765 1
Legend: Abbreviations: AF = allele frequency; CPD = cigarettes per day; s.e. = standard error; SNP = single-nucleotide polymorphism.
⁎ Bonferroni-adjusted p-value. The p-values were adjusted by a factor of 9.
159S.P. David et al. / EBioMedicine 4 (2016) 153–161mechanisms other than increased smoking quantity to confer higher
lung cancer susceptibility. The present study was unable to address
this question.
Our hypothesis was that if polymorphisms associated with altered
CHRNA3-A5-B4 expression concomitantly moderated both increased
cigarette consumption and intrinsic risk for lung cancer, that gene by
environment (smoking quantity) interactions would be additive. How-
ever, these data suggest a different scenario. Themagnitude of increased
risk associated with one or two risk alleles appeared to attenuate in in-
dividuals smokingmore CPD, even though therewas a positive relation-
ship between CPD and risk of lung cancer. For example, individualswho
smoked on average 5 CPD had 80% higher odds of developing lung can-
cer if they possessed one A risk allele for rs2036527 (odds ratio (OR) =
1.84; 95% conﬁdence interval (CI) 1.41, 2.40), whereas they were 200%
more likely to develop lung cancer if they possessed two A alleles
(OR = 3.05, 95% CI: 1.78, 5.19). However, an individual who smoked
20 CPD was about twice as likely to develop lung cancer if they hadFig. 3. Interaction between SNPs and cigarettes per day and risk of lung cancer. Legend: Odds r
with one or more risk alleles for each SNP by cigarettes per day (x-axis).one A allele (OR = 1.96, 95% CI: 1.56, 2.51) but slightly more than
twice as likely to develop lung cancer if they had two risk alleles
(OR = 2.53, 95% CI: 1.16, 5.62).
It is noteworthy that in our data, diminishing odds ratios for lung
cancer with increasing smoking intensity were only observed for indi-
viduals with the highest genetic risk (i.e., possessing two risk alleles).
Reduced effects of increased smoking intensity on lung cancer risk are
a phenomenon that has been modeled in other studies (Lubin et al.,
2007a), and in multiple tobacco-attributable cancers (Lubin et al.,
2007b), that included studies of African-Americans. It has been shown
that there is reduced exposure to N′-nitrosonornicotine (NNK) and its
metabolites (NNAL) at higher levels of cotinine exposure (Lubin et al.,
2007c; Lubin and Caporaso, 2006).
Mechanisms of increased lung cancer susceptibility independent of
smoking quantity for individuals with chromosome 15q25.1 high-risk
genotypes are not entirely clear. Multiple studies have demonstrated
associations between SNPs in chromosome 15q25.1 and lung cancer inatio for incident lung cancer (y-axis) in multicenter case–control study and in participants
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have shown that a gene in this region (PSMA4) has been associatedwith
cancer cell proliferation and apoptosis (Liu et al., 2009) and another
gene (IREB2) (Fehringer et al., 2012) has been associated with lung
cancer risk. A SNP (rs3813570) in the PSMA4 gene approached
genome-wide signiﬁcance in the STOMP Consortium meta-analysis
and a variant in IREB2 (rs17405217) was associated with lung cancer
risk in the present investigation and others (Walsh et al., 2013; Walsh
et al., 2012). It is therefore possible that the high degree of linkage dis-
equilibrium between chromosome 15q25.1 variants in cholinergic
genes associated with increased smoking intensity and those in neigh-
boring genes linked to tumor proliferationmay result in frequent haplo-
types capturing both heightened cigarette exposure and susceptibility
to lung cancer pathogenesis. However, additional research is needed
to conﬁrm mechanisms of potential concomitant dual risk of exposure
and cancer susceptibility.
It is worth noting that pack-years were not associated with the
genotypes tested and this variable did not interact with genotype to
predict lung cancer risk in either study population. While this may be
the result of a combination of lack of sensitivity due to recall bias and
sample size (Castaldi et al., 2011), a previously published study of
smoking persistence in African-Americans examined pack-years of ex-
posure, accounting for periods of non-smoking, and reported multiple
statistically signiﬁcant associations with SNPs in the 15q25.1 region
(Hamidovic et al., 2011). Thus, it is not entirely clear why this measure
of smoking exposure was not robust in our investigation. However,
given pre-clinical evidence of much higher nicotine self-administration
in CHRNA5 knockout mice (Fowler et al., 2011; Fowler et al., 2013;
Fowler and Kenny, 2014), it is possible that humans with altered
CHRNA5 expression possess a phenotype of markedly greater alveolar to-
bacco smoke exposure vis-à-vis increased smoking quantity, intensity
and puff volume over a lifetime (Ware et al., 2012), which in turn por-
tends greater overall exposure than can be captured with granularity
using the measured phenotypes of pack-years or average CPD.
This study has some limitations. While we did have sufﬁcient statis-
tical power in an a priori power analysis to detect effects sizes of at least
2.1 (assuming power N .8, allele frequencies ≥0.15 and at least 85 lung
cancer cases), in analyses not corrected for multiple comparison,
adjusting for multiple comparisons may limited our ability to detect
statistically-signiﬁcant effects robust to multiple corrections. We did
not have access to spirometry or diagnostic data for conditions such as
COPD and emphysema to enable analyses of potential mediating effects
of smoking quantity on the relationship between the CHRNA3-A5-B4
locus and lung cancer risk, which has been demonstrated in
European-ancestry studies (El-Zein et al., 2012). Another limitation of
the present investigation is that the WHI SHARe analyses did not in-
clude males. However, we previously published a genome-wide meta-
analyses of smoking quantity that included both genders of African-
Americans that conﬁrmed rs2036527 in association with CPD after
adjusting for gender (David et al., 2012), but nonetheless, we cannot
rule out the possibility that other SNPs nominally associated with CPD
in this investigation could be moderated by sex. In addition, we did
not have information on type of cigarettes smoked such asmenthol cig-
arettes, smoking topography or plasma cotinine levels. However, two
earlier investigations of genetic predictors of lung cancer risk in
African-Americans by Amos and colleagues did not show any differen-
tial effect of menthol on the relationship between SNP and lung cancer
risk (Walsh et al., 2013; Amos et al., 2010).
5. Conclusions
Additional research is needed using larger sample sizes to conduct
mediation analyses and including preclinical data to conﬁrm that the in-
creased lung cancer risk of associated SNPs is causally driven entirely by
increased smoking intensity. However, our results add to the growing
literature pointing towards rs2036527 as an informative polymorphismfor smoking exposure and lung cancer risk in African-Americans, who
may beneﬁt fromenhanced preventive interventions for smoking cessa-
tion treatment (Zhu et al., 2014) and genetically-informed lung cancer
screening interventions (Young et al., 2012).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.01.002.
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